Aurobindo Pharma reported 1.15B in Interest Expense on Debt for its fiscal quarter ending in March of 2025.


Interest Expense On Debt Change Date
Cipla 140.5M 300K Jun/2025
Divis Laboratories Ltd 30M 20M Jun/2025
Dr.Reddys Laboratories 830M 174M Jun/2025
Hindustan Unilever 800M 320M Mar/2025
Sun Pharmaceuticals 748M 256.6M Jun/2025
UPL 9.14B 1.84B Mar/2025